Single-molecule mitochondrial DNA sequencing shows no evidence of CpG methylation in human cells and tissues. Issue 22 (29th November 2021)

• Record Type: Journal Article
• Authors: Bicci, Iacopo; Calabrese, Claudia; Golder, Zoe J; Gomez-Duran, Aurora; Chinnery, Patrick F
• Is Part Of: Nucleic acids research. Volume 49:Issue 22(2021)
• Page Start: 12757
• Page End: 12768
• Publication Date: 2021-11-29
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gkab1179
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: Methylation on CpG residues is one of the most important epigenetic modifications of nuclear DNA, regulating gene expression. Methylation of mitochondrial DNA (mtDNA) has been studied using whole genome bisulfite sequencing (WGBS), but recent evidence has uncovered technical issues which introduce a potential bias during methylation quantification. Here, we validate the technical concerns of WGBS, and develop and assess the accuracy of a new protocol for mtDNA nucleotide variant-specific methylation using single-molecule Oxford Nanopore Sequencing (ONS). Our approach circumvents confounders by enriching for full-length molecules over nuclear DNA. Variant calling analysis against showed that 99.5% of homoplasmic mtDNA variants can be reliably identified providing there is adequate sequencing depth. We show that some of the mtDNA methylation signal detected by ONS is due to sequence-specific false positives introduced by the technique. The residual signal was observed across several human primary and cancer cell lines and multiple human tissues, but was always below the error threshold modelled using negative controls. We conclude that there is no evidence for CpG methylation in human mtDNA, thus resolving previous controversies. Additionally, we developed a reliable protocol to study epigenetic modifications of mtDNA at single-molecule and single-base resolution, with potential applications beyond CpG methylation.